Navigation Links
Effective, safe anthrax vaccine can be grown in tobacco plants

s.

Researchers then injected the vaccine into mice to immunize them against anthrax and sent the mice to NIH labs, where they survived doses of anthrax several times stronger than the amounts to which humans have been exposed.

The next step for the anthrax vaccine would involve a company working with NIH to conduct clinical trials. Human subjects would be injected only with the vaccine and not with anthrax itself, and scientists would then check the subjects' immunity levels. The vaccine later could be mass-produced and stockpiled for emergencies.

Daniell conducted his study with part of a $1 million NIH grant and a $2 million U.S. Department of Agriculture grant that cover research related to genetic engineering in plants as a way to produce therapies for several diseases. Daniell's work holds promise for treating other diseases, including diabetes and hepatitis, and improving vaccines for plague, cholera and other bioterrorism agents.

Daniell is developing a new technology that would enable vaccines to be administered orally and allow effective and less expensive treatments to be more accessible worldwide. He believes fruits and vegetables such as carrots and tomatoes are the keys to figuring out a way for people to take anthrax vaccines orally in capsules of dried plant cells that contain correct doses of the protective antigen.

If that research is successful, the needs for requiring doctors to administer the shots and for shipping vaccines in refrigerated trucks, both of which can be especially difficult in poorer nations, would be eliminated.

The military now administers the vaccine with three shots in the first four weeks, three more in the next 17 months and then annual booster shots, according to the Pentagon (www.anthrax.mil).

Daniell, who is the first UCF Trustee Chair in Life Sciences, began teaching at UCF in 1998. He has formed a biotechnology company called Ch
'"/>

Source:University of Central Florida


Page: 1 2 3

Related biology news :

1. Scientists seek answers on what activates deadly anthrax spores
2. Antibodies from plants protect against anthrax
3. Defensins neutralize anthrax toxin
4. Critical step traced in anthrax infection
5. US Army plans to bulk-buy anthrax
6. New antibody shows promise as cure for anthrax
7. UCSD study finds anthrax toxins also harmful to fruit flies
8. Driver of anthrax toxicity could lead to late-stage therapy
9. Scientists design potent anthrax toxin inhibitor
10. Newly discovered protein kills anthrax bacteria by exploding their cell walls
11. Combating anthrax: Results of study published this month as researchers look for a better vaccine

Post Your Comments:
(Date:12/1/2009)...unce the publication of results from its Phase II ...rability of its novel, intranasal drug/device prod...sitis with nasal polyps in Rhinology , the offici...logic Societies. , Chronic rhinosinusitis with ...cantly reduce a patient,s quality of life, causing...
(Date:12/1/2009)...researchers have developed a tumor-attacking viru... growth of new tumor blood vessels. , Their rese...lls oncolytic viruses might be more effective ag... gene for a protein that inhibits blood-vessel gro...ally produced in the brain. In this study, an onco...
(Date:12/1/2009)...rks can be solved with a new technique that identi...their victims, according to a University of Florid...logous to analyzing human fingerprints, scientists...hark bites to the jaws and teeth of the powerful p...ernational Shark Attack File, which is housed at U...
Breaking Biology News(10 mins):New data on highly effective treatment for chronic rhinosinusitis with nasal polyps 2Tumor-attacking virus strikes with 'one-two punch' 2New forensic technique gives clues about sharks from bite damage 2New forensic technique gives clues about sharks from bite damage 3Caraco Pharmaceutical Laboratories Ltd Markets Nicardipine Hydrochloride Injection 6376 1Caraco Pharmaceutical Laboratories Ltd Markets Nicardipine Hydrochloride Injection 6376 2Cancers sweet tooth may be weakness 10788 1Cancers sweet tooth may be weakness 10788 2HCA Names Joe Sowell Senior Vice President 26amp 3B Chief Development Officer 61620 1HCA Names Joe Sowell Senior Vice President 26amp 3B Chief Development Officer 61620 2
... Conn. A joint Yale-Peking University center that...erstanding of plant biology will receive five year...nto Company, a leading provider of agricultural te...es and a series of plant biology-related programs ...olecular Genetics and Agrobiotechnology , a multid...
...computers to compare portions of the human genome ...l have discovered some 300 previously unidentified...red genes already known., The discovery is based o...enetic code that do something useful for the organ...orted by Adam Siepel, Cornell assistant professor ...
...rne diseases such as malaria and dengue cause suff...auses at least one million deaths annually, and is...e of five. In addition to the human toll, these d...y communities that can least afford it. Various a...secticides, vaccine development, and preventive me...
Other Biology News:Monsanto expands sponsorship for Peking-Yale Joint Agrobiotechnology Center 2Evolutionary comparison finds new human genes 2Evolutionary comparison finds new human genes 3Selfish DNA and the Genetic Control of Vector-Borne Diseases 2Selfish DNA and the Genetic Control of Vector-Borne Diseases 3
(Date:12/1/2009)...c. 1 Reportlinker.com announces th...s catalogue: ,, Emerging Clinical Trial Locati...ging healthcare and regulatory environment ,, ...nical-Trial-Locations---Eastern-Europe-Market-dyna...vironment.html ,, Over the last decade pharmac...
(Date:12/1/2009)...ty Leader Richard Gephardt Brings Together A-List ...nities for "Best and Brightest Forum on Medical I...wswire-USNewswire/ -- Several of New Jersey,s most..., medicine and technology gathered today at the Li...medical innovation in New Jersey, and throughout t...
(Date:12/1/2009)...l., Dec. 1 Prairie Heart Institute...was recently awarded two statuettes at the first-e... York City. The CLIO Healthcare Awards recognizes ...re advertising industry and is an extension of the...wards competitions for advertising, design and int...
(Date:12/1/2009)...ax, Inc. today announced a collaborative research ...aimed at evaluating EpiVax’s proprietary Tre...detrimental immune responses to certain drugs. In ...EpiVax Tregitope technology will be evaluated for ...apeutics. , (Vocus) Decem...
Breaking Biology Technology:Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 2New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 3New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 4New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 5Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards 2EpiVax, Inc. forms Collaborative Research Agreement with Roche to Develop Tregitope Technology 2EpiVax, Inc. forms Collaborative Research Agreement with Roche to Develop Tregitope Technology 3
... 2009 Senomyx, Inc. (Nasdaq: SNMX ) will releas... fiscal year ending December 31, 2008 on Thursday,...financial markets. The Company will also host a c...0 a.m. Eastern Time (8:00 a.m. Pacific Time) that ...ill provide a business update and will discuss the...
...o help eye specialists better understand the impac...eir patients, Viscira teamed up with an industry-l...a virtual experience of having neovascular (wet) a... San Francisco, CA (PRWEB) January ...and the impact of one of the fastest growing eye d...
...exsun Corp, a leader in renewable energy and biofu...e appointment of David Pyrce as its Chief Executiv... Los Angeles (PRWEB) Janua...energy and biofuels development and production, to...s Chief Executive Officer and member of the Board ...
Other Biology Technology:SENOMYX, INC. fourth quarter AND FISCAL YEAR-END 2008 Earnings conference call scheduled for February 12, 2009 2Looking at AMD Through Patients' Eyes: Viscira Virtual Exhibit Educates Physicians by Personalizing Serious Eye Disease 2Looking at AMD Through Patients' Eyes: Viscira Virtual Exhibit Educates Physicians by Personalizing Serious Eye Disease 3Nexsun Corp Names Industry Executive David Pyrce as Chief Executive Officer 2
Mouse Anti-Kusabira Orange Monoclonal Antibody, Unconjugated, Clone 2G9 from MBL International
Goat Anti-SPFH2 Polyclonal Antibody, Unconjugated from Abcam
Goat Anti-Als2 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Kusabira Orange Monoclonal Antibody, Unconjugated, Clone 2G9 from MBL International
Biology Products: